Testing three drugs together for advanced pancreatic cancer

Plain-English translation of NCT06761027 on ClinicalTrials.gov ↗ · Source last updated January 2025 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a combination of three medications — mFOLFIRINOX (a chemotherapy), anlotinib (a targeted therapy), and sintilimab (an immunotherapy) — given together to treat advanced pancreatic cancer. The study wants to see if this three-drug combination works well and is safe for people who have not received cancer treatment before. Researchers will also look for signs that might help predict who will benefit most from this treatment.

Pancreatic cancer is very difficult to treat, especially when it has spread beyond the pancreas or cannot be removed with surgery. Doctors hope that combining three different types of cancer-fighting medications — each working in a different way — might be more effective than using them separately or using standard chemotherapy alone.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced pancreatic cancer (either locally advanced or metastatic) confirmed by a biopsy or tissue sample
you have never received cancer treatment before
you have at least one tumor that can be measured on imaging scans
you are in good enough health to tolerate this treatment (ECOG score 0–1, meaning you can do most normal activities)
you are expected to live at least 3 months

You likely don't qualify if…

you have already received chemotherapy, radiation, targeted therapy, immunotherapy, or other cancer treatments
you are allergic to any of the three medications in this trial
you have brain tumors with symptoms, or brain tumors that were only recently controlled
you have very extensive liver tumors taking up more than 70% of your liver
you have active autoimmune diseases (such as rheumatoid arthritis, lupus, or inflammatory bowel disease) that are likely to flare up

What participation looks like

You would take anlotinib as an oral tablet at home for 14 days every 3 weeks, along with the other two medications given by your medical team. The study has two phases: first, a small group will receive the treatment to make sure the dose is safe, and then a larger group will join to test how well it works. You will have regular clinic visits for blood tests, imaging scans, and check-ups to monitor how you are responding and watch for side effects.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(4 sites)

China

First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian

Fujian Provincial Hospital, Fuzhou, Fujian

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian

Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian